Trial reportAmerican journal of Alzheimer's disease and other dementias
Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease.
Trial report in American journal of Alzheimer's disease and other dementias. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic literature review of the methodology for developing pharmacotherapeutic interchange guidelines and their implementation in hospitals and ambulatory care settings.European journal of clinical pharmacology · 2019Pooled it
- Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension.Journal of Alzheimer's disease : JAD · 2026Trial
- Article
- Donepezil-induced bradycardia in a schizophrenic patient with comorbid neurocognitive disorder: a case report and review of the literature.Journal of medical case reports · 2024Review
- Strategies for Continued Successful Treatment in Patients with Alzheimer's Disease: An Overview of Switching Between Pharmacological Agents.Current Alzheimer research · 2018Review
- Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2015Observational
- Observational
- Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.Drugs & aging · 2011Review
- Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.CNS drugs · 2011Review
- Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.Drugs · 2011Review
- Five skills psychiatrists should have in order to provide patients with optimal ethical care.Innovations in clinical neuroscience · 2011Article
- An atypical cutaneous reaction to rivastigmine transdermal patch.Journal of allergy · 2011Article
- Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease.CNS neuroscience & therapeutics · 2010Review
- Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.CNS neuroscience & therapeutics · 2010Review
- Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results.Primary care companion to the Journal of clinical psychiatry · 2010Article
- A prospective study on the use of rivastigmine transdermal patch in Alzheimer's dementia in a routine clinical setting.Dementia & neuropsychologiaArticle
- Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan.Dementia and geriatric cognitive disorders extraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEvaluate safety and tolerability of switching from donepezil to rivastigmine transdermal patch in patients with mild to moderate Alzheimer's disease.
methodsProspective, parallel-group, open-label study to evaluate immediate or delayed switch from 5-10 mg/day donepezil to 4.6 mg/24 h rivastigmine following a 4-week treatment period.
resultsRates of discontinuation due to any reason or adverse events were similar between groups. Incidences of gastrointestinal adverse events were 3.8% in the immediate and 0.8% in the delayed switch group. No patients discontinued secondary to nausea and vomiting. Discontinuations due to application site reactions were low (2.3%). Asymptomatic bradycardia was more common following the immediate switch (2.3% vs 0%); however, these patients had coexisting cardiac comorbidities.
conclusionBoth switch strategies were safe and well tolerated. The majority of patients may be able to switch directly to rivastigmine patches without a withdrawal period. Appropriate clinical judgment should be used for patients with existing bradycardia or receiving beta blockers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.